Tag: USFDA-approved neuroendocrine tumor treatment

Home / USFDA-approved neuroendocrine tumor treatment

Categories

Cabozantinib is approved by the USFDA for adults and pediatric patients 12 years of age and older with pNET and epNET

On March 26, 2025, the Food and Drug Administration sanctioned cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients aged 12 and older with previously treated, unresectable, locall...
usfda-approved-neuroendocrine-tumor-treatment

Scan the code